Lanean...
Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science
Although GLP-1 (glucagon like peptide-1) based therapies (GLP-1 agonists and dipeptidyl peptidase-4 inhibitors) is currently playing a cornerstone role in the treatment of type 2 diabetes, dilemma does exist about some of its basic physiology. So far, we know that GLP-1 is secreted by the direct act...
Gorde:
| Argitaratua izan da: | Indian J Endocrinol Metab |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Medknow Publications & Media Pvt Ltd
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4287769/ https://ncbi.nlm.nih.gov/pubmed/25593851 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.146881 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|